Residential School on Medicinal Chemistry and Biology in Drug Discovery

 

Drew University’s Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed)

IMPORTANT INFORMATION

Please email resmed@drew.edu to be added on the notification list for ResMed 2022 or if you have any questions.

About ResMed

Drew University’s Residential School on Medicinal Chemistry and Biology in Drug Discovery (ResMed) course was held June 7-11, 2021 (with intro lecture on June 4th) virtually considering the ongoing coronavirus pandemic. Dates for 2022 ResMed are TBD.

ResMed is a graduate level course designed for chemists and biologists  interested in broadening their understanding of the fundamental principles of drug discovery research and pre-clinical development. Scientists from related disciplines would also gain a clearer appreciation for the processes and methods important to drug discovery through clinical development.

Keynote 2021

Michael J. Sofia, Ph.D. is Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. a company focused on the discovery and development of therapies to cure hepatitis B. Previously Mike was Sr. Vice President of Chemistry at Pharmasset, Inc. Mike has also held research and research management positions at Gilead Sciences, Bristol-Myers Squibb, Transcell Technologies and Eli Lilly and Company.

Registrations for 2021 is now closed

Please email resmed@drew.edu to be added on the notification list for 2022 ResMed.